Standout Papers

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy 2013 2026 2017 2021 702
  1. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy (2013)
    Hubing Shi, Willy Hugo et al. Cancer Discovery
  2. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial (2016)
    Patrick Schöffski, Sant P. Chawla et al. The Lancet
  3. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial (2016)
    William D. Tap, Robin L. Jones et al. The Lancet

Immediate Impact

11 by Nobel laureates 11 from Science/Nature 77 standout
Sub-graph 1 of 18

Citing Papers

Cutaneous melanoma
2023 Standout
Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
2022 Standout
6 intermediate papers

Works of Bartosz Chmielowski being referenced

Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy
2022
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
2014
and 8 more

Author Peers

Author Last Decade Papers Cites
Bartosz Chmielowski 4349 1765 2542 1769 179 6.8k
Jeffrey A. Drebin 6455 2282 3187 1783 204 10.8k
Mario Santinami 4893 1008 3101 2447 163 7.7k
Patrizia Nanni 2499 1127 2729 2611 171 6.4k
Winan J. van Houdt 2685 1365 1598 462 161 5.0k
Evan J. Lipson 5692 1543 1366 2178 123 7.4k
Michael A. Curran 3866 942 1628 3553 124 6.7k
Luigi Tornillo 3236 1703 2925 1317 149 8.1k
Paola Queirolo 5242 932 2947 2450 229 7.1k
Vanna Chiarion‐Sileni 7787 2708 4266 3175 295 11.4k
Justin M. Balko 5880 2172 5001 2640 146 11.0k

All Works

Loading papers...

Rankless by CCL
2026